Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Telithromycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 1.00 |
| ▸ | CYP3A5 | P20815 | 6/20 | 1.00 |
| ▸ | CYP3A7 | P24462 | 6/20 | 1.00 |
| ▸ | CYP3A43 | Q9HB55 | 6/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 1.00 |
| ▸ | GNRHR | P30968 | 2/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.51 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Telithromycin SCHEMBL19518975 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP3A5CYP3A7CYP3A43KCNH2 | |
| Telithromycin SCHEMBL14521662 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP3A5CYP3A7CYP3A43KCNH2 | |
| Telithromycin SCHEMBL18035669 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP3A5CYP3A7CYP3A43KCNH2 | |
| Telithromycin SCHEMBL12858721 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP3A5CYP3A7CYP3A43KCNH2 | |
| Telithromycin SCHEMBL14268636 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP3A5CYP3A7CYP3A43KCNH2 | |
| Telithromycin SCHEMBL10819900 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP3A5CYP3A7CYP3A43KCNH2 | |
| Telithromycin SCHEMBL15387603 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP3A5CYP3A7CYP3A43KCNH2 | |
| Telithromycin SCHEMBL5100 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP3A5CYP3A7CYP3A43KCNH2 | |
| Telithromycin SCHEMBL1878591 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP3A5CYP3A7CYP3A43KCNH2 | |
| Telithromycin SCHEMBL31576166 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP3A5CYP3A7CYP3A43KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160280718-A1 | NOVEL ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME (US) | 2016-09-29 | — | — | US | disclosed |
| US-9200026-B2 | Antibacterial agents | MERCK SHARP & DOHME CORP. (US) | 2015-12-01 | — | — | US | disclosed |
| US-8343936-B2 | Antibacterial agents | OPTIMER PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120071429-A1 | Novel antibacterial agents | TETARD, INC. | 2012-03-22 | — | — | US | disclosed |
| US-8012943-B2 | Antibacterial agents | OPTIMER PHARMACEUTICALS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-7601695-B2 | 11-N-[4-(4-Pyridin-3-yl-imidazol-1-yl)-butyl]-6-O-methyl-5-O-(3-dimethylamino-2-hydroxy-propoxy)-3-oxo-erythronolide A, 11,12-carbamate; functionalized macrolides; antiviral, antiprotozoal, anticancer and antigastrointestinal | OPTIMER PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090209593-A1 | NOVEL ANTIBACTERIAL AGENTS | TETARD, INC. | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280718-A1 | NOVEL ANTIBACTERIAL AGENTS | MRPL21, MRPL12, CTSA | CYP3A4 4333/4885CYP3A5 4316/4885CYP3A7 4101/4885 |
| US-20120071429-A1 | Novel antibacterial agents | MRPL21, CTSA, MRPL12 | CYP3A4 4197/4885CYP3A5 4377/4885CYP3A7 3751/4885 |
| US-20090209593-A1 | NOVEL ANTIBACTERIAL AGENTS | MRPL21, MRPL12, CTSA | CYP3A4 4368/4885CYP3A5 4340/4885CYP3A7 4154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.